Education and Training
The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration
The purpose if this study is to assess the response to nerve root infiltration therapy in patients with cervical or lumbar disc herniations.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- procedure: Cervical nerve root infiltration
- procedure: Lumbar nerve root infiltration
- drug: Mephamesone
- drug: 0.5% bupivacaine (Bupivacain®)
- drug: Kenacort®
Eligibility
Inclusion Criteria:
- Symptomatic (pain) one-level cervical (C3-C8) or lumbar (L1-S1) radiculopathy with
radiological evidence of discal nerve root compression
- Minimum VAS of 20/100
- Age between 18 - 70 years
Exclusion Criteria:
- Multilevel disc herniations with multiple symptomatic nerve root compressions
- Higher motor deficits (Paresis M 0-3 of a peripheral muscle)
- Age < 18 or > 70 years
- Pregnancy
- Allergic reaction against steroids or local anaesthetic
- Bleeding disorder (Tc < 100.000/ul, Quick <50%, INR > 1.5, abnormal PTT)
- Known bleeding diathesis
- Continued anticoagulants (Warfarin = Marcoumar must be bridged with low- or
high-molecular heparin; commonly, intake of Aspirin or Clopidogrel is no
contraindication for infiltration therapy but is routinely paused when possible)
- Pseudoradicular pain (e.g. in facet arthrosis, iliosacral arthrosis...) - as evaluated
to the best of the knowledge of the admitting physician and radiologist performing the
infiltration
- Osseous spinal or foraminal stenosis
- Myelopathy
- Severe scoliosis
- Active neoplasm
- History of spinal infection / spondylodiscitis
- History of spinal surgery or previous infiltration therapy on the currently painful
segment
- Rheumatic disease
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting